Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

This lawsuit is for anyone who acquired securities in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from September 17, 2024 through May 26, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by failing to timely disclose to investors that the Company made a substantive amendment to the protocol of the Company’s Phase 2 trial of its Danon disease treatment, RP-A501.

On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event (“SAE”) occurred. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from September 17, 2024 through May 26, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.